Oppenheimer assigned a buy recommendation or CBAY with a $14 target price.
G
BlackRock has a position in CBAY worth $30.9 million .
l
There is a big need of liver inflammation treatments.
S
lets rock
j
I think what is hurting the share price is the utter lack of communication from the company. No news on any trials, no information on when earnings will be, no information of any kind. It’s been almost 3 months without anything...No wonder people are selling their shares. They should put something out just to let everyone know they are making some sort of progress. Cmon CBAY board let us know your alive!
j
It seems as though the earnings report should have been released by now...Does anyone have any info on this?
B
so I just got a free share from robinhood did a lil dd and correct me if I'm wrong but all I see as of right now is a company borrowing alot of money with no product available yet to sell and make profits. Or I'm I missing something? btw not bashing just inquiring
Like Yogi said IT AIN'T OVER TILL IT'S OVER BUT THIS ONE IS OVER. I've been in since $3.20 ,left at $4.50. not going to make alot but I'm Out of CBAY
G
Seems the 5,160,000 shares that were reported shorted on January 29th are making money.
I
CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.
W
No bottom
B
Think we will get some news soon.....
G
March 8th, 2021 , Zacks upgraded CBAY from sell to hold.
J
Cbay has plenty cash and no debt. Just bought 3k shares.... LFG
G
On marketwatch, they reported that as of Jan 29th, short interest was up +31%, totaling 5,160,000 shares of CBAY shorted.